
Opinion|Videos|April 11, 2025
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What safety data do you take into consideration when prescribing an IL-17 inhibitor?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
3
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
4
Dermatology Times Spot Test: December 14, 2025
5




















